261 related articles for article (PubMed ID: 36324594)
1. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
Shi Y; Pei R; Liu S
Front Oncol; 2022; 12():833773. PubMed ID: 36324594
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
Wu B; Gu X; Zhang Q
J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Guan H; Liu G; Xie F; Sheng Y; Shi L
Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
Li W; Qian L; Li W; Chen X; He H; Tian H; Zhao Y; Wang X; Cui J
Exp Ther Med; 2021 Apr; 21(4):343. PubMed ID: 33732316
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Rui M; Li H
Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
[No Abstract] [Full Text] [Related]
7. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL
Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Huo G; Song Y; Liu W; Cao X; Chen P
Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
[No Abstract] [Full Text] [Related]
11. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
Xu X; Fang N; Li H; Liu Y; Yang F; Li X
Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Khoo T; Gao L
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
[No Abstract] [Full Text] [Related]
17. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Luo X; Zhou Z; Zeng X; Liu Q
Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
[No Abstract] [Full Text] [Related]
18. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.
Guan H; Wang C; Chen C; Han S; Zhao Z
Front Oncol; 2022; 12():819674. PubMed ID: 35785198
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
Liu H; Wang Y; He Q
Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]